
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4091175/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Personalized Management of Pheochromocytoma and Paraganglioma. Endocrine Reviews, 2022, 43, 199-239.	8.9	127

- Sporadic Primary Pheochromocytoma: A Prospective Intraindividual Comparison of Six Imaging Tests (CT, MRI, and PET/CT Using ⁶⁸Ga-DOTATATE, FDG, ¹⁸F-FDOPA, and) Tj ETQq0 0 0 rgBT /@@erlock 112 Tf 50 69 2

3	Germline <i>SUCLG2</i> Variants in Patients With Pheochromocytoma and Paraganglioma. Journal of the National Cancer Institute, 2022, 114, 130-138.	3.0	21
4	Differences in clinical presentation and management between pre- and postsurgical diagnoses of urinary bladder paraganglioma: is there clinical relevance? A systematic review. World Journal of Urology, 2022, 40, 385-390.	1.2	8
5	New Insights on the Genetics of Pheochromocytoma and Paraganglioma and Its Clinical Implications. Cancers, 2022, 14, 594.	1.7	33
6	Personalized drug testing in human pheochromocytoma/paraganglioma primary cultures. Endocrine-Related Cancer, 2022, 29, 285-306.	1.6	12
7	Head/neck paragangliomas: focus on tumor location, mutational status and plasma methoxytyramine. Endocrine-Related Cancer, 2022, 29, 213-224.	1.6	12
8	Somatic Mosaicism of EPAS1 Mutations in Pacak-Zhuang Syndrome. Endocrine Practice, 2022, , .	1.1	0
9	Functional Imaging of Neuroendocrine Tumors: Stacking the Odds in a Patient's Favor. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e3953-e3954.	1.8	2
10	Determinants of disease-specific survival in patients with and without metastatic pheochromocytoma and paraganglioma. European Journal of Cancer, 2022, 169, 32-41.	1.3	18
11	Supportive management of patients with pheochromocytoma/paraganglioma undergoing noninvasive treatment. Current Opinion in Endocrinology, Diabetes and Obesity, 2022, 29, 294-301.	1.2	3
12	Phaeochromocytoma and pregnancy: looking towards better outcomes, less fear, and valuable recommendations. Lancet Diabetes and Endocrinology,the, 2021, 9, 2-3.	5.5	6
13	What Have We Learned from Molecular Biology of Paragangliomas and Pheochromocytomas?. Endocrine Pathology, 2021, 32, 134-153.	5.2	22
14	Pheochromocytoma Hypertensive Crisis. Contemporary Endocrinology, 2021, , 137-145.	0.3	0
15	Functional significance of germline EPAS1 variants. Endocrine-Related Cancer, 2021, 28, 97-109.	1.6	6
16	Developmental vascular malformations in EPAS1 gain-of-function syndrome. JCI Insight, 2021, 6, .	2.3	14
17	High-Specific-Activity-131I-MIBG versus 177Lu-DOTATATE Targeted Radionuclide Therapy for Metastatic Pheochromocytoma and Paraganglioma. Clinical Cancer Research, 2021, 27, 2989-2995.	3.2	42
18	Mannan-BAM, TLR Ligands, Anti-CD40 Antibody (MBTA) Vaccine Immunotherapy: A Review of Current Evidence and Applications in Glioblastoma. International Journal of Molecular Sciences, 2021, 22, 3455.	1.8	7

KAREL PACAK

#	Article	IF	CITATIONS
19	Succinate Mediates Tumorigenic Effects via Succinate Receptor 1: Potential for New Targeted Treatment Strategies in Succinate Dehydrogenase Deficient Paragangliomas. Frontiers in Endocrinology, 2021, 12, 589451.	1.5	25
20	Somatostatin Receptors and Analogs in Pheochromocytoma and Paraganglioma: Old Players in a New Precision Medicine World. Frontiers in Endocrinology, 2021, 12, 625312.	1.5	25
21	Imaging of Small Intestine Neuroendocrine Neoplasms: Is SSTR PET the Holy Grail?. Journal of Nuclear Medicine, 2021, 62, 1347-1348.	2.8	3
22	Mannan-BAM, TLR ligands, and anti-CD40 immunotherapy in established murine pancreatic adenocarcinoma: understanding therapeutic potentials and limitations. Cancer Immunology, Immunotherapy, 2021, 70, 3303-3312.	2.0	5
23	International consensus on initial screening and follow-up of asymptomatic SDHx mutation carriers. Nature Reviews Endocrinology, 2021, 17, 435-444.	4.3	80
24	Diagnostic Accuracy of Salivary Metanephrines in Pheochromocytomas and Paragangliomas. Clinical Chemistry, 2021, 67, 1090-1097.	1.5	2
25	Clinically Advanced Pheochromocytomas and Paragangliomas: A Comprehensive Genomic Profiling Study. Cancers, 2021, 13, 3312.	1.7	9
26	Imaging of Pheochromocytoma and Paraganglioma. Journal of Nuclear Medicine, 2021, 62, 1033-1042.	2.8	50
27	Reactive Oxygen Species: A Promising Therapeutic Target for SDHx-Mutated Pheochromocytoma and Paraganglioma. Cancers, 2021, 13, 3769.	1.7	3
28	A Clinical Challenge: Endocrine and Imaging Investigations of Adrenal Masses. Journal of Nuclear Medicine, 2021, 62, 26S-33S.	2.8	8
29	Identification of Immune Cell Infiltration in Murine Pheochromocytoma during Combined Mannan-BAM, TLR Ligand, and Anti-CD40 Antibody-Based Immunotherapy. Cancers, 2021, 13, 3942.	1.7	7
30	Identification of Isocitrate Dehydrogenase 2 (IDH2) Mutation in Carotid Body Paraganglioma. Frontiers in Endocrinology, 2021, 12, 731096.	1.5	5
31	Variants and Pitfalls of PET/CT in Neuroendocrine Tumors. Seminars in Nuclear Medicine, 2021, 51, 519-528.	2.5	11
32	A long noncoding RNA–microRNA expression signature predicts metastatic signature in pheochromocytomas and paragangliomas. Endocrine, 2021, , 1.	1.1	1
33	Systemic Radiopharmaceutical Therapy of Pheochromocytoma and Paraganglioma. Journal of Nuclear Medicine, 2021, 62, 1192-1199.	2.8	14
34	A novel liquid biopsy (NETest) identifies paragangliomas and pheochromocytomas with high accuracy. Endocrine-Related Cancer, 2021, 28, 731-744.	1.6	9
35	Quantitative biomarkers allow the diagnosis of head and neck paraganglioma on multiparametric MRI. European Journal of Radiology, 2021, 143, 109911.	1.2	3
36	The Global Reading Room: Nuclear Medicine Imaging of Suspected Paraganglioma. American Journal of Roentgenology, 2021, 217, 1008-1009.	1.0	1

#	Article	IF	CITATIONS
37	Deep Membrane Proteome Profiling Reveals Overexpression of Prostate-Specific Membrane Antigen (PSMA) in High-Risk Human Paraganglioma and Pheochromocytoma, Suggesting New Theranostic Opportunity. Molecules, 2021, 26, 6567.	1.7	4
38	Surgical Resection of Pheochromocytomas and Paragangliomas is Associated with Lower Cholesterol Levels. World Journal of Surgery, 2020, 44, 552-560.	0.8	4
39	Long intergenic noncoding RNA profiles of pheochromocytoma and paraganglioma: A novel prognostic biomarker. International Journal of Cancer, 2020, 146, 2326-2335.	2.3	14
40	Prognostic and predictive value of nuclear imaging in endocrine oncology. Endocrine, 2020, 67, 9-19.	1.1	9
41	Vascular Changes in the Retina and Choroid of Patients With EPAS1 Gain-of-Function Mutation Syndrome. JAMA Ophthalmology, 2020, 138, 148.	1.4	4
42	Some Considerations in Treating Malignant Head and Neck Paragangliomas. JAMA Otolaryngology - Head and Neck Surgery, 2020, 146, 209.	1.2	2
43	Pheochromocytoma and Paraganglioma Patients With Poor Survival Often Show Brown Adipose Tissue Activation. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 1176-1185.	1.8	18
44	Phosphoprotein-based biomarkers as predictors for cancer therapy. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 18401-18411.	3.3	25
45	Pathophysiology and Acute Management of Tachyarrhythmias in Pheochromocytoma. Journal of the American College of Cardiology, 2020, 76, 451-464.	1.2	30
46	Induction of Immune Response against Metastatic Tumors via Vaccination of Mannanâ€BAM, TLR Ligands, and Antiâ€CD40 Antibody (MBTA). Advanced Therapeutics, 2020, 3, 2000044.	1.6	11
47	Catecholamine physiology and its implications in patients with COVID-19. Lancet Diabetes and Endocrinology,the, 2020, 8, 978-986.	5.5	49
48	Emerging Treatments for Advanced/Metastatic Pheochromocytoma and Paraganglioma. Current Treatment Options in Oncology, 2020, 21, 85.	1.3	43
49	Phaeochromocytoma — advances through science, collaboration and spreading the word. Nature Reviews Endocrinology, 2020, 16, 621-622.	4.3	8
50	Neuraxial dysraphism in EPAS1-associated syndrome due to improper mesenchymal transition. Neurology: Genetics, 2020, 6, e414.	0.9	5
51	Metabolomics, machine learning and immunohistochemistry to predict succinate dehydrogenase mutational status in phaeochromocytomas and paragangliomas. Journal of Pathology, 2020, 251, 378-387.	2.1	23
52	Targeting pheochromocytoma/paraganglioma with polyamine inhibitors. Metabolism: Clinical and Experimental, 2020, 110, 154297.	1.5	11
53	Therapeutic Targeting of <i>SDHB</i> -Mutated Pheochromocytoma/Paraganglioma with Pharmacologic Ascorbic Acid. Clinical Cancer Research, 2020, 26, 3868-3880.	3.2	29
54	Molecular Imaging in the Era of Precision Medicine: Paraganglioma as a Template for Understanding Multiple Levels of Analysis. Journal of Nuclear Medicine, 2020, 61, 646-648.	2.8	1

#	Article	IF	CITATIONS
55	Genetics, diagnosis, management and future directions of research of phaeochromocytoma and paraganglioma: a position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension. Journal of Hypertension, 2020, 38, 1443-1456.	0.3	190
56	Clinical characteristics and outcomes of SDHB-related pheochromocytoma and paraganglioma in children and adolescents. Journal of Cancer Research and Clinical Oncology, 2020, 146, 1051-1063.	1.2	30
57	Clinical manifestations of Pacakâ€Zhuang syndrome in a male pediatric patient. Pediatric Blood and Cancer, 2020, 67, e28096.	0.8	4
58	Role of 68Ga-DOTATATE PET/CT in a Case of SDHB-Related Pterygopalatine Fossa Paraganglioma Successfully Controlled with Octreotide. Nuclear Medicine and Molecular Imaging, 2020, 54, 48-52.	0.6	9
59	Targeting NRF2-Governed Glutathione Synthesis for SDHB-Mutated Pheochromocytoma and Paraganglioma. Cancers, 2020, 12, 280.	1.7	23
60	Genetic Determinants of Pheochromocytoma and Paraganglioma Imaging Phenotypes. Journal of Nuclear Medicine, 2020, 61, 643-645.	2.8	7
61	C-Terminal, but Not Intact, FGF23 and EPO Are Strongly Correlatively Elevated in Patients With Gain-of-Function Mutations in HIF2A: Clinical Evidence for EPO Regulating FGF23. Journal of Bone and Mineral Research, 2020, 36, 315-321.	3.1	9
62	Case Report: Primary Hypothyroidism Associated With Lutetium 177-DOTATATE Therapy for Metastatic Paraganglioma. Frontiers in Endocrinology, 2020, 11, 587065.	1.5	4
63	Comprehensive review of evaluation and management of cardiac paragangliomas. Heart, 2020, 106, 1202-1210.	1.2	22
64	A xenograft and cell line model of SDH-deficient pheochromocytoma derived from Sdhb+/â^' rats. Endocrine-Related Cancer, 2020, 27, 337-354.	1.6	16
65	Epidural anesthesia and hypotension in pheochromocytoma and paraganglioma. Endocrine-Related Cancer, 2020, 27, 519-527.	1.6	7
66	HIF2α supports pro-metastatic behavior in pheochromocytomas/paragangliomas. Endocrine-Related Cancer, 2020, 27, 625-640.	1.6	33
67	Pheochromocytoma/paraganglioma: recent updates in genetics, biochemistry, immunohistochemistry, metabolomics, imaging and therapeutic options. Gland Surgery, 2020, 9, 105-123.	0.5	37
68	18F-FDOPA PET/CT accurately identifies MEN1-associated pheochromocytoma. Endocrinology, Diabetes and Metabolism Case Reports, 2020, 2020, .	0.2	4
69	A novel germline gain-of-function HIF2A mutation in hepatocellular carcinoma with polycythemia. Aging, 2020, 12, 5781-5791.	1.4	4
70	Metabolome-guided genomics to identify pathogenic variants in isocitrate dehydrogenase, fumarate hydratase, and succinate dehydrogenase genes in pheochromocytoma and paraganglioma. Genetics in Medicine, 2019, 21, 705-717.	1.1	60
71	Postoperative Management in Patients with Pheochromocytoma and Paraganglioma. Cancers, 2019, 11, 936.	1.7	25
72	Current experts' views on precision nuclear medicine imaging of phaeochromocytoma and paraganglioma. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 2223-2224.	3.3	6

#	Article	IF	CITATIONS
73	Medullary Thyroid Carcinoma: An Update on Imaging. Journal of Thyroid Research, 2019, 2019, 1-17.	0.5	36
74	European Association of Nuclear Medicine Practice Guideline/Society of Nuclear Medicine and Molecular Imaging Procedure Standard 2019 for radionuclide imaging of phaeochromocytoma and paraganglioma. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 2112-2137.	3.3	208
75	Adipocyte β-arrestin-2 is essential for maintaining whole body glucose and energy homeostasis. Nature Communications, 2019, 10, 2936.	5.8	43
76	Current Management of Pheochromocytoma/Paraganglioma: A Guide for the Practicing Clinician in the Era of Precision Medicine. Cancers, 2019, 11, 1505.	1.7	120
77	Pseudopheochromocytoma. Endocrinology and Metabolism Clinics of North America, 2019, 48, 751-764.	1.2	9
78	Coley's immunotherapy revived: Innate immunity as a link in priming cancer cells for an attack by adaptive immunity. Seminars in Oncology, 2019, 46, 385-392.	0.8	11
79	Tumor multifocality with vagus nerve involvement as a phenotypic marker of <i>SDHD</i> mutation in patients with head and neck paragangliomas: A ¹⁸ Fâ€FDOPA PET/CT study. Head and Neck, 2019, 41, 1565-1571.	0.9	4
80	Exploring the link between tumour metabolism and succinate dehydrogenase deficiency: A ¹⁸ Fâ€FDOPA PET/CT study in head and neck paragangliomas. Clinical Endocrinology, 2019, 91, 879-884.	1.2	3
81	Synergistic Highly Potent Targeted Drug Combinations in Different Pheochromocytoma Models Including Human Tumor Cultures. Endocrinology, 2019, 160, 2600-2617.	1.4	24
82	Optimizing Genetic Workup in Pheochromocytoma and Paraganglioma by Integrating Diagnostic and Research Approaches. Cancers, 2019, 11, 809.	1.7	23
83	More on Ivabradine in Tachycardia with Paraganglioma. New England Journal of Medicine, 2019, 380, 2590-2590.	13.9	0
84	MicroRNA-210 May Be a Preoperative Biomarker of Malignant Pheochromocytomas and Paragangliomas. Journal of Surgical Research, 2019, 243, 1-7.	0.8	11
85	Chiari Malformation Type 1 in EPAS1-Associated Syndrome. International Journal of Molecular Sciences, 2019, 20, 2819.	1.8	8
86	A Transgenic Mouse Model of Pacak–Zhuang Syndrome with An Epas1 Gain-of-Function Mutation. Cancers, 2019, 11, 667.	1.7	22
87	Gallbladder Paraganglioma Associated with SDHD Mutation: a Potential Pitfall on 18F-FDOPA PET Imaging. Nuclear Medicine and Molecular Imaging, 2019, 53, 144-147.	0.6	6
88	Impact of Extrinsic and Intrinsic Hypoxia on Catecholamine Biosynthesis in Absence or Presence of Hif2α in Pheochromocytoma Cells. Cancers, 2019, 11, 594.	1.7	24
89	The Significant Reduction or Complete Eradication of Subcutaneous and Metastatic Lesions in a Pheochromocytoma Mouse Model after Immunotherapy Using Mannan-BAM, TLR Ligands, and Anti-CD40. Cancers, 2019, 11, 654.	1.7	21
90	A Previously Unrecognized Monocytic Component of Pheochromocytoma and Paraganglioma. Endocrine Pathology, 2019, 30, 90-95.	5.2	14

#	Article	IF	CITATIONS
91	Gsα deficiency in the dorsomedial hypothalamus leads to obesity, hyperphagia, and reduced thermogenesis associated with impaired leptin signaling. Molecular Metabolism, 2019, 25, 142-153.	3.0	8
92	A Necessity, not a Second Thought: Pre-Operative Alpha-Adrenoceptor Blockade in Pheochromocytoma Patients. Endocrine Practice, 2019, 25, 200-201.	1.1	1
93	Clinical, Diagnostic, and Treatment Characteristics of SDHA-Related Metastatic Pheochromocytoma and Paraganglioma. Frontiers in Oncology, 2019, 9, 53.	1.3	39
94	Ivabradine in Catecholamine-Induced Tachycardia in a Patient with Paraganglioma. New England Journal of Medicine, 2019, 380, 1284-1286.	13.9	9
95	Eruption of Metastatic Paraganglioma After Successful Therapy with 177Lu/90Y-DOTATOC and 177Lu-DOTATATE. Nuclear Medicine and Molecular Imaging, 2019, 53, 223-230.	0.6	9
96	Pheochromocytomas and Paragangliomas: From Genetic Diversity to Targeted Therapies. Cancers, 2019, 11, 436.	1.7	33
97	Catecholamine-Induced Cardiomyopathy in Pheochromocytoma: How to Manage a Rare Complication in a Rare Disease?. Hormone and Metabolic Research, 2019, 51, 458-469.	0.7	51
98	Reactivation of Dihydroorotate Dehydrogenase-Driven Pyrimidine Biosynthesis Restores Tumor Growth of Respiration-Deficient Cancer Cells. Cell Metabolism, 2019, 29, 399-416.e10.	7.2	190
99	Nonmosaic somatic <i>HIF2A</i> mutations associated with late onset polycythemiaâ€paraganglioma syndrome: Newly recognized subclass of polycythemiaâ€paraganglioma syndrome. Cancer, 2019, 125, 1258-1266.	2.0	11
100	The 3PAs: An Update on the Association of Pheochromocytomas, Paragangliomas, and Pituitary Tumors. Hormone and Metabolic Research, 2019, 51, 419-436.	0.7	22
101	Metastatic Phaeochromocytoma: Spinning Towards More Promising Treatment Options. Experimental and Clinical Endocrinology and Diabetes, 2019, 127, 117-128.	0.6	40
102	Why Take the Risk? We Only Live Once: The Dangers Associated with Neglecting a Pre-Operative Alpha Adrenoceptor Blockade in Pheochromocytoma Patients. Endocrine Practice, 2019, 25, 106-108.	1.1	14
103	Radioguided Surgery With Gallium 68 Dotatate for Patients With Neuroendocrine Tumors. JAMA Surgery, 2019, 154, 40.	2.2	34
104	Preoperative 18F-FDG PET/CT in Pheochromocytomas and Paragangliomas Allows for Precision Surgery. Annals of Surgery, 2019, 269, 741-747.	2.1	15
105	Diagnostic Investigation of Lesions Associated with Succinate Dehydrogenase Defects. Hormone and Metabolic Research, 2019, 51, 414-418.	0.7	5
106	A high rate of modestly elevated plasma normetanephrine in a population referred for suspected PPGL when measured in a seated position. European Journal of Endocrinology, 2019, 181, 301-309.	1.9	25
107	Genotype–phenotype correlations in pheochromocytoma and paraganglioma: a systematic review and individual patient meta-analysis. Endocrine-Related Cancer, 2019, 26, 539-550.	1.6	87
108	Molecular imaging and radionuclide therapy of pheochromocytoma and paraganglioma in the era of genomic characterization of disease subgroups. Endocrine-Related Cancer, 2019, 26, R627-R652.	1.6	72

KAREL PACAK

#	Article	IF	CITATIONS
109	Characteristic CT features of pheochromocytomas - probability model calculation tool based on a multicentric study. Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia, 2019, 163, 212-219.	0.2	15
110	18F-FDOPA PET/CT Imaging of MAX-Related Pheochromocytoma. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 1574-1582.	1.8	27
111	Continued Tumor Reduction of Metastatic Pheochromocytoma/Paraganglioma Harboring Succinate Dehydrogenase Subunit B Mutations with Cyclical Chemotherapy. Cellular and Molecular Neurobiology, 2018, 38, 1099-1106.	1.7	27
112	Targeting NAD+/PARP DNA Repair Pathway as a Novel Therapeutic Approach to <i>SDHB</i> -Mutated Cluster I Pheochromocytoma and Paraganglioma. Clinical Cancer Research, 2018, 24, 3423-3432.	3.2	57
113	Molecular imaging and theranostic approaches in pheochromocytoma and paraganglioma. Cell and Tissue Research, 2018, 372, 393-401.	1.5	37
114	Successful induction therapy with sequential CVD followed by high-dose lanreotide in for metastatic SDHB paraganglioma: Case report. Journal of Clinical and Translational Endocrinology: Case Reports, 2018, 7, 8-13.	0.4	3
115	Genomic Landscape of Pheochromocytoma and Paraganglioma. Trends in Cancer, 2018, 4, 6-9.	3.8	71
116	Prognostic Utility of Total 68Ga-DOTATATE-Avid Tumor Volume in Patients With Neuroendocrine Tumors. Gastroenterology, 2018, 154, 998-1008.e1.	0.6	62
117	Deletion of the von Hippel-Lindau Gene in Hemangioblasts Causes Hemangioblastoma-like Lesions in Murine Retina. Cancer Research, 2018, 78, 1266-1274.	0.4	16
118	Successful Second-Line Metronomic Temozolomide in Metastatic Paraganglioma: Case Reports and Review of the Literature. Clinical Medicine Insights: Oncology, 2018, 12, 117955491876336.	0.6	27
119	A novel splicing site IRP1 somatic mutation in a patient with pheochromocytoma and JAK2V617F positive polycythemia vera: a case report. BMC Cancer, 2018, 18, 286.	1.1	15
120	Pheochromocytoma/Paraganglioma: Update on Diagnosis and Management. Contemporary Endocrinology, 2018, , 261-310.	0.3	2
121	Quantitative 18F-DOPA PET/CT in pheochromocytoma: the relationship between tumor secretion and its biochemical phenotype. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 278-282.	3.3	28
122	Superiority of 68Ga-DOTATATE over 18F-FDG and anatomic imaging in the detection of succinate dehydrogenase mutation (SDHx)-related pheochromocytoma and paraganglioma in the pediatric population. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 787-797.	3.3	64
123	New Challenges in Nuclear Endocrinology. Journal of Nuclear Medicine, 2018, 59, 573-574.	2.8	0
124	Preoperative genetic testing in pheochromocytomas and paragangliomas influences the surgical approach and the extent of adrenal surgery. Surgery, 2018, 163, 191-196.	1.0	32
125	Blood collection in unstressed, conscious, and freely moving mice through implantation of catheters in the jugular vein: a new simplified protocol. Physiological Reports, 2018, 6, e13904.	0.7	10
126	RNA-Sequencing Analysis of Adrenocortical Carcinoma, Pheochromocytoma and Paraganglioma from a Pan-Cancer Perspective. Cancers, 2018, 10, 518.	1.7	10

#	Article	IF	CITATIONS
127	New insights on the pathogenesis of paraganglioma and pheochromocytoma. F1000Research, 2018, 7, 1500.	0.8	17
128	SDHD Gene Mutations: Looking Beyond Head and Neck Tumors. AACE Clinical Case Reports, 2018, 4, 186-190.	0.4	0
129	Primary fibroblast co-culture stimulates growth and metabolism in Sdhb-impaired mouse pheochromocytoma MTT cells. Cell and Tissue Research, 2018, 374, 473-485.	1.5	23
130	Prospective evaluation of ⁶⁸ Gaâ€ <scp>DOTATATE PET</scp> / <scp>CT</scp> in limited disease neuroendocrine tumours and/or elevated serum neuroendocrine biomarkers. Clinical Endocrinology, 2018, 89, 155-163.	1.2	11
131	Molecular evaluation of a sporadic paraganglioma with concurrent IDH1 and ATRX mutations. Endocrine, 2018, 61, 216-223.	1.1	7
132	A Clinical Roadmap to Investigate the Genetic Basis of Pediatric Pheochromocytoma: Which Genes Should Physicians Think About?. International Journal of Endocrinology, 2018, 2018, 1-14.	0.6	11
133	Role of MDH2 pathogenic variant in pheochromocytoma and paraganglioma patients. Genetics in Medicine, 2018, 20, 1652-1662.	1.1	45
134	Update of Pheochromocytoma Syndromes: Genetics, Biochemical Evaluation, and Imaging. Frontiers in Endocrinology, 2018, 9, 515.	1.5	82
135	Mathematical modeling of disease dynamics in SDHB- and SDHD-related paraganglioma: Further step in understanding hereditary tumor differences and future therapeutic strategies. PLoS ONE, 2018, 13, e0201303.	1.1	4
136	The role of CSK3 and its reversal with GSK3 antagonism in everolimus resistance. Endocrine-Related Cancer, 2018, 25, 893-908.	1.6	24
137	Alternative assembly of respiratory complex II connects energy stress to metabolic checkpoints. Nature Communications, 2018, 9, 2221.	5.8	44
138	Leptomeningeal dissemination of a low-grade lumbar paraganglioma: case report. Journal of Neurosurgery: Spine, 2017, 26, 501-506.	0.9	10
139	Comprehensive Molecular Characterization of Pheochromocytoma and Paraganglioma. Cancer Cell, 2017, 31, 181-193.	7.7	532
140	Radionuclide Imaging of Head and Neck Paragangliomas. , 2017, , 269-294.		0
141	Implications of SDHB genetic testing in patients with sporadic pheochromocytoma. Langenbeck's Archives of Surgery, 2017, 402, 787-798.	0.8	4
142	Surgical Management of Wild-Type Gastrointestinal Stromal Tumors: A Report From the National Institutes of Health Pediatric and Wildtype GIST Clinic. Journal of Clinical Oncology, 2017, 35, 523-528.	0.8	58
143	Emerging role of dopamine in neovascularization of pheochromocytoma and paraganglioma. FASEB Journal, 2017, 31, 2226-2240.	0.2	12
144	PET Imaging for Endocrine Malignancies: From Woe to Go. Journal of Nuclear Medicine, 2017, 58, 878-880.	2.8	2

#	Article	IF	CITATIONS
145	Mitochondrial Complex II: At the Crossroads. Trends in Biochemical Sciences, 2017, 42, 312-325.	3.7	192
146	Paraganglioma of the organ of Zuckerkandl associated with a somatic HIF21± mutation: A case report. Oncology Letters, 2017, 13, 1083-1086.	0.8	4
147	Accuracy of recommended sampling and assay methods for the determination of plasma-free and urinary fractionated metanephrines in the diagnosis of pheochromocytoma and paraganglioma: a systematic review. Endocrine, 2017, 56, 495-503.	1.1	79
148	Characteristics of Pediatric vs Adult Pheochromocytomas and Paragangliomas. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 1122-1132.	1.8	120
149	18F-fluorodihydroxyphenylalanine PET/CT in pheochromocytoma and paraganglioma: relation to genotype and amino acid transport system L. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 812-821.	3.3	20
150	The Evolving Role of Succinate in Tumor Metabolism: An ¹⁸ F-FDG–Based Study. Journal of Nuclear Medicine, 2017, 58, 1749-1755.	2.8	27
151	SDHB-related pheochromocytoma and paraganglioma penetrance and genotype–phenotype correlations. Journal of Cancer Research and Clinical Oncology, 2017, 143, 1421-1435.	1.2	63
152	Functional Imaging Signature of Patients Presenting with Polycythemia/Paraganglioma Syndromes. Journal of Nuclear Medicine, 2017, 58, 1236-1242.	2.8	29
153	Precision Medicine in Adrenal Disorders: the Next Generation. Endocrine Practice, 2017, 23, 672-679.	1.1	3
154	Precision Medicine: An Update on Genotype/Biochemical Phenotype Relationships in Pheochromocytoma/Paraganglioma Patients. Endocrine Practice, 2017, 23, 690-704.	1.1	58
155	Association between neuroendocrine tumors biomarkers and primary tumor site and disease type based on total 68Ga-DOTATATE-Avid tumor volume measurements. European Journal of Endocrinology, 2017, 176, 575-582.	1.9	38
156	Radionuclide Imaging of Chromaffin Cell Tumors. , 2017, , 295-319.		0
157	HIF-2alpha: Achilles' heel of pseudohypoxic subtype paraganglioma and other related conditions. European Journal of Cancer, 2017, 86, 1-4.	1.3	16
158	The microenvironment induces collective migration in SDHB-silenced mouse pheochromocytoma spheroids. Endocrine-Related Cancer, 2017, 24, 555-564.	1.6	26
159	New Insights into the Nuclear Imaging Phenotypes of Cluster 1 Pheochromocytoma and Paraganglioma. Trends in Endocrinology and Metabolism, 2017, 28, 807-817.	3.1	34
160	Metanephrines for Evaluating Palpitations and Flushing. JAMA - Journal of the American Medical Association, 2017, 318, 385.	3.8	11
161	Mapping of human brown adipose tissue in lean and obese young men. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 8649-8654.	3.3	370
162	Relevant Discordance Between 68Ga-DOTATATE and 68Ga-DOTANOC in SDHB-Related Metastatic Paraganglioma. Clinical Nuclear Medicine, 2017, 42, 211-213.	0.7	3

#	Article	IF	CITATIONS
163	New Perspectives on Pheochromocytoma and Paraganglioma: Toward a Molecular Classification. Endocrine Reviews, 2017, 38, 489-515.	8.9	241
164	Recent advances in the imaging of pheochromocytomas and paragangliomas. International Journal of Endocrine Oncology, 2017, 4, 137-144.	0.4	0
165	PheoSeq. Journal of Molecular Diagnostics, 2017, 19, 575-588.	1.2	63
166	Pathological and Genetic Characterization of Bilateral Adrenomedullary Hyperplasia in a Patient with Germline MAX Mutation. Endocrine Pathology, 2017, 28, 302-307.	5.2	25
167	SDHB mutation status and tumor size but not tumor grade are important predictors of clinical outcome in pheochromocytoma and abdominal paraganglioma. Surgery, 2017, 161, 230-239.	1.0	60
168	Management of Pheochromocytoma and Paraganglioma. , 2017, , 179-206.		0
169	Reply: 68Ga-DOTATATE PET/CT Versus MRI: Why the Comparison of 68Ga-DOTATATE PET/CT to an Appropriate MRI Protocol Is Essential. Journal of Nuclear Medicine, 2017, 58, 185-185.	2.8	3
170	Imaging Modalities for Pheochromocytoma and Paraganglioma. , 2017, , 125-138.		0
171	Pathology of Human Pheochromocytoma and Paraganglioma Xenografts in NSG Mice. Endocrine Pathology, 2017, 28, 2-6.	5.2	19
172	Pediatric patients with pheochromocytoma and paraganglioma should have routine preoperative genetic testing for common susceptibility genes in addition to imaging to detect extra-adrenal and metastatic tumors. Surgery, 2017, 161, 220-227.	1.0	47
173	Bortezomib Alone and in Combination With Salinosporamid A Induces Apoptosis and Promotes Pheochromocytoma Cell Death In Vitro and in Female Nude Mice. Endocrinology, 2017, 158, 3097-3108.	1.4	10
174	Anthracyclines suppress pheochromocytoma cell characteristics, including metastasis, through inhibition of the hypoxia signaling pathway. Oncotarget, 2017, 8, 22313-22324.	0.8	29
175	Cardiometabolic risk factors and health behaviors in family caregivers. PLoS ONE, 2017, 12, e0176408.	1.1	10
176	Vorinostat suppresses hypoxia signaling by modulating nuclear translocation of hypoxia inducible factor 1 alpha. Oncotarget, 2017, 8, 56110-56125.	0.8	64
177	Uncommon spreading of primary malignant paraganglioma in a patient with SDHB mutation. Case Reports in Internal Medicine, 2016, 4, 63.	0.0	0
178	Total 18F-FDG PET/CT Metabolic Tumor Volume Is Associated With Postoperative Biochemical Response in Patients With Metastatic Pheochromocytomas and Paragangliomas. Annals of Surgery, 2016, 263, 582-587.	2.1	10
179	18F-DOPA: the versatile radiopharmaceutical. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 1187-1189.	3.3	15
180	Endocrine tumors associated with the vagus nerve. Endocrine-Related Cancer, 2016, 23, R371-R379.	1.6	9

#	Article	IF	CITATIONS
181	Hypoxia-Inducible Factor 2α Mutation-Related Paragangliomas Classify as Discrete Pseudohypoxic Subcluster. Neoplasia, 2016, 18, 567-576.	2.3	16
182	Novel insights into the polycythemia–paraganglioma–somatostatinoma syndrome. Endocrine-Related Cancer, 2016, 23, 899-908.	1.6	62
183	HIF2A gain-of-function mutations detected in duodenal gangliocytic paraganglioma. Endocrine-Related Cancer, 2016, 23, L13-L16.	1.6	20
184	The Author's Reply: inappropriate adrenoreceptor blockade prior to pheochromocytoma removal – â€~A timely reappraisal'. Clinical Endocrinology, 2016, 85, 990-991.	1.2	0
185	Nuclear Medicine in Cancer Theranostics: Beyond the Target. Journal of Nuclear Medicine, 2016, 57, 1659-1660.	2.8	14
186	Molecular Imaging of Gastroenteropancreatic Neuroendocrine Tumors: Current Status and Future Directions. Journal of Nuclear Medicine, 2016, 57, 1949-1956.	2.8	119
187	Pheochromocytoma: The First Metabolic Endocrine Cancer. Clinical Cancer Research, 2016, 22, 5001-5011.	3.2	59
188	AN AGGRESSIVE TEMPORAL BONE SDHC PARAGANGLIOMA ASSOCIATED WITH INCREASED HIF-2 $\hat{1}$ ± SIGNALING. Endocrine Practice, 2016, 22, 190-195.	1.1	6
189	Functional Imaging Experience in a Germline Fumarate Hydratase Mutation–Positive Patient With Pheochromocytoma and Paraganglioma. AACE Clinical Case Reports, 2016, 2, e176-e181.	0.4	9
190	Characteristics And Outcomes Of Metastatic Sdhb And Sporadic Pheochromocytoma/Paraganglioma: An National Institutes Of Health Study. Endocrine Practice, 2016, 22, 302-314.	1.1	110
191	Are patients with hormonally functional phaeochromocytoma and paraganglioma initially receiving a proper adrenoceptor blockade? A retrospective cohort study. Clinical Endocrinology, 2016, 85, 62-69.	1.2	14
192	Rapidly Growing Chest Wall Mass in a Case of Sporadic Metastatic Paraganglioma. Clinical Nuclear Medicine, 2016, 41, 399-400.	0.7	2
193	Radiopharmaceuticals in paraganglioma imaging: too many members on board?. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 391-393.	3.3	6
194	PET/CT comparing 68Ga-DOTATATE and other radiopharmaceuticals and in comparison with CT/MRI for the localization of sporadic metastatic pheochromocytoma and paraganglioma. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 1784-1791.	3.3	138
195	Molecular Subtypes of <i>KIT/PDGFRA</i> Wild-Type Gastrointestinal Stromal Tumors. JAMA Oncology, 2016, 2, 922.	3.4	291
196	Somatic gain-of-function HIF2A mutations in sporadic central nervous system hemangioblastomas. Journal of Neuro-Oncology, 2016, 126, 473-481.	1.4	18
197	InÂvivo detection of catecholamines byÂmagnetic resonance spectroscopy: AÂpotential specific biomarker for the diagnosis of pheochromocytoma. Surgery, 2016, 159, 1231-1233.	1.0	10
198	Documenting stress in caregivers of transplantation patients: initial evidence of HPA dysregulation. Stress, 2016, 19, 175-184.	0.8	31

#	Article	IF	CITATIONS
199	Mass spectrometric quantification of salivary metanephrines—A study in healthy subjects. Clinical Biochemistry, 2016, 49, 983-988.	0.8	10
200	Prospective comparison of 68Ga-DOTATATE and 18F-FDOPA PET/CT in patients with various pheochromocytomas and paragangliomas with emphasis on sporadic cases. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 1248-1257.	3.3	96
201	Prospective Study of ⁶⁸ Ga-DOTATATE Positron Emission Tomography/Computed Tomography for Detecting Gastro-Entero-Pancreatic Neuroendocrine Tumors and Unknown Primary Sites. Journal of Clinical Oncology, 2016, 34, 588-596.	0.8	287
202	⁶⁸ Ga-DOTATATE PET/CT in the Localization of Head and Neck Paragangliomas Compared with Other Functional Imaging Modalities and CT/MRI. Journal of Nuclear Medicine, 2016, 57, 186-191.	2.8	148
203	Determination of the unmetabolised 18F-FDG fraction by using an extension of simplified kinetic analysis method: clinical evaluation in paragangliomas. Medical and Biological Engineering and Computing, 2016, 54, 103-111.	1.6	9
204	Carney triad can be (rarely) associated with germline succinate dehydrogenase defects. European Journal of Human Genetics, 2016, 24, 569-573.	1.4	57
205	Hypoxia potentiates the cytotoxic effect of piperlongumine in pheochromocytoma models. Oncotarget, 2016, 7, 40531-40545.	0.8	10
206	Pheochromocytoma Resection: The Rule of Surgical Divergence. AACE Clinical Case Reports, 2016, 2, e78-e79.	0.4	2
207	Somatic mosaicism of EPAS1 mutations in the syndrome of paraganglioma and somatostatinoma associated with polycythemia. Human Genome Variation, 2015, 2, 15053.	0.4	26
208	Multidisciplinary management of locally advanced and widely metastatic paraganglioma in a patient with lifeâ€ŧhreatening compressive symptoms. Head and Neck, 2015, 37, E205-8.	0.9	2
209	Urinary Bladder Paragangliomas. American Journal of Surgical Pathology, 2015, 39, 1488-1492.	2.1	20
210	SDHB/SDHA immunohistochemistry in pheochromocytomas and paragangliomas: a multicenter interobserver variation analysis using virtual microscopy: a Multinational Study of the European Network for the Study of Adrenal Tumors (ENS@T). Modern Pathology, 2015, 28, 807-821.	2.9	176
211	Lack of utility of SDHB mutation testing in adrenergic metastatic phaeochromocytoma. European Journal of Endocrinology, 2015, 172, 89-95.	1.9	17
212	Pheochromocytoma Screening Initiation and Frequency in von Hippel-Lindau Syndrome. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 4498-4504.	1.8	60
213	Metabolome Profiling by HRMAS NMR Spectroscopy of Pheochromocytomas and Paragangliomas Detects SDH Deficiency: Clinical and Pathophysiological Implications. Neoplasia, 2015, 17, 55-65.	2.3	60
214	Pituitary Adenoma With Paraganglioma/Pheochromocytoma (3PAs) and Succinate Dehydrogenase Defects in Humans and Mice. Journal of Clinical Endocrinology and Metabolism, 2015, 100, E710-E719.	1.8	121
215	Results of 68Gallium-DOTATATE PET/CT Scanning in Patients with Multiple Endocrine Neoplasia Type 1. Journal of the American College of Surgeons, 2015, 221, 509-517.	0.2	72

Pheochromocytoma and Paraganglioma Syndromes. , 2015, , 449-454.

#	Article	IF	CITATIONS
217	Pheochromocytoma: Gasping for Air. Hormones and Cancer, 2015, 6, 191-205.	4.9	26
218	Magnetic resonance spectroscopy of paragangliomas: new insights into in vivo metabolomics. Endocrine-Related Cancer, 2015, 22, M1-M8.	1.6	34
219	Association of urinary bladder paragangliomas with germline mutations in the SDHB and VHL genes. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 167.e13-167.e20.	0.8	24
220	Preoperative Imaging Features are Associated with Surgical Complications Following Carotid Body Tumor Resection. World Journal of Surgery, 2015, 39, 2084-2089.	0.8	15
221	Succinate Dehydrogenase Gene Mutations in Cardiac Paragangliomas. American Journal of Cardiology, 2015, 115, 1753-1759.	0.7	30
222	Superiority of [68Ga]-DOTATATE PET/CT to Other Functional Imaging Modalities in the Localization of <i>SDHB</i> -Associated Metastatic Pheochromocytoma and Paraganglioma. Clinical Cancer Research, 2015, 21, 3888-3895.	3.2	223
223	Pheochromocytoma and Paraganglioma. Endocrine Practice, 2015, 21, 406-412.	1.1	54
224	18F-FLT PET/CT in the Evaluation of Pheochromocytomas and Paragangliomas: A Pilot Study. Journal of Nuclear Medicine, 2015, 56, 1849-1854.	2.8	4
225	Carney triad, SDH-deficient tumors, and Sdhb+/â^' mice share abnormal mitochondria. Endocrine-Related Cancer, 2015, 22, 345-352.	1.6	23
226	Pendrin localizes to the adrenal medulla and modulates catecholamine release. American Journal of Physiology - Endocrinology and Metabolism, 2015, 309, E534-E545.	1.8	23
227	Application and Dosimetric Requirements for Gallium-68–labeled Somatostatin Analogues in Targeted Radionuclide Therapy for Gastroenteropancreatic Neuroendocrine Tumors. PET Clinics, 2015, 10, 477-486.	1.5	14
228	Inhibitory Effect of the Noncamptothecin Topoisomerase I Inhibitor LMP-400 on Female Mice Models and Human Pheochromocytoma Cells. Endocrinology, 2015, 156, 4094-4104.	1.4	12
229	15 YEARS OF PARAGANGLIOMA: Imaging and imaging-based treatment of pheochromocytoma and paraganglioma. Endocrine-Related Cancer, 2015, 22, T135-T145.	1.6	84
230	Germ-line PHD1 and PHD2 mutations detected in patients with pheochromocytoma/paraganglioma-polycythemia. Journal of Molecular Medicine, 2015, 93, 93-104.	1.7	118
231	Potential therapeutic target for malignant paragangliomas: ATP synthase on the surface of paraganglioma cells. American Journal of Cancer Research, 2015, 5, 1558-70.	1.4	10
232	High-Throughput Screening for the Identification of New Therapeutic Options for Metastatic Pheochromocytoma and Paraganglioma. PLoS ONE, 2014, 9, e90458.	1.1	9
233	Cytocidal Activities of Topoisomerase 1 Inhibitors and 5-Azacytidine against Pheochromocytoma/Paraganglioma Cells in Primary Human Tumor Cultures and Mouse Cell Lines. PLoS ONE, 2014, 9, e87807.	1.1	14
234	ZNF367 Inhibits Cancer Progression and Is Targeted by miR-195. PLoS ONE, 2014, 9, e101423.	1.1	36

KAREL PACAK

#	Article	IF	CITATIONS
235	Krebs Cycle Metabolite Profiling for Identification and Stratification of Pheochromocytomas/Paragangliomas due to Succinate Dehydrogenase Deficiency. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 3903-3911.	1.8	111
236	Protocol for the Examination of Specimens From Patients With Pheochromocytomas and Extra-Adrenal Paragangliomas. Archives of Pathology and Laboratory Medicine, 2014, 138, 182-188.	1.2	52
237	External Beam Radiation Therapy in Treatment of Malignant Pheochromocytoma and Paraganglioma. Frontiers in Oncology, 2014, 4, 166.	1.3	51
238	Succinate-to-Fumarate Ratio as a New Metabolic Marker to Detect the Presence of SDHB/D-related Paraganglioma: Initial Experimental and Ex Vivo Findings. Endocrinology, 2014, 155, 27-32.	1.4	63
239	Combination of 13-Cis Retinoic Acid and Lovastatin: Marked Antitumor Potential In Vivo in a Pheochromocytoma Allograft Model in Female Athymic Nude Mice. Endocrinology, 2014, 155, 2377-2390.	1.4	15
240	Counseling patients with succinate dehydrogenase subunit defects: genetics, preventive guidelines, and dealing with uncertainty. Journal of Pediatric Endocrinology and Metabolism, 2014, 27, 837-44.	0.4	12
241	¹⁸ Fâ€ <scp>FDG PET</scp> / <scp>CT</scp> as a predictor of hereditary head and neck paragangliomas. European Journal of Clinical Investigation, 2014, 44, 325-332.	1.7	30
242	Clinical utility of chromogranin A in <i><scp>SDH</scp>xâ€</i> related paragangliomas. European Journal of Clinical Investigation, 2014, 44, 365-371.	1.7	40
243	Diagnosis and preoperative imaging of multiple endocrine neoplasia type 2: current status and future directions. Clinical Endocrinology, 2014, 81, 317-328.	1.2	24
244	Integrated Whole-Body PET/MRI With 18F-FDG, 18F-FDOPA, and 18F-FDA in Paragangliomas in Comparison With PET/CT. Clinical Nuclear Medicine, 2014, 39, 243-250.	0.7	19
245	Current views on cell metabolism in SDHx-related pheochromocytoma and paraganglioma. Endocrine-Related Cancer, 2014, 21, R261-R277.	1.6	31
246	Monoamine Oxidase B Prompts Mitochondrial and Cardiac Dysfunction in Pressure Overloaded Hearts. Antioxidants and Redox Signaling, 2014, 20, 267-280.	2.5	135
247	The Adrenal Medulla and Extra-adrenal Paraganglia: Then and Now. Endocrine Pathology, 2014, 25, 49-58.	5.2	39
248	The Genetic Basis of Pheochromocytoma and Paraganglioma: Implications for Management. Urology, 2014, 83, 1225-1232.	0.5	40
249	Irisin and FGF21 Are Cold-Induced Endocrine Activators of Brown Fat Function in Humans. Cell Metabolism, 2014, 19, 302-309.	7.2	643
250	Familial pheochromocytomas and paragangliomas. Molecular and Cellular Endocrinology, 2014, 386, 92-100.	1.6	47
251	Genetics, Diagnosis, and Management of Medullary Thyroid Carcinoma and Pheochromocytoma/Paraganglioma. Endocrine Practice, 2014, 20, 176-187.	1.1	14
252	Pheochromocytoma and paraganglioma: Diagnosis, genetics, management, and treatment. Current Problems in Cancer, 2014, 38, 7-41.	1.0	163

#	Article	IF	CITATIONS
253	Ocular Manifestations of Hypoxia-Inducible Factor-2α Paraganglioma-Somatostatinoma-Polycythemia Syndrome. Ophthalmology, 2014, 121, 2291-2293.	2.5	23
254	Current Approaches and Recent Developments in the Management of Head and Neck Paragangliomas. Endocrine Reviews, 2014, 35, 795-819.	8.9	124
255	Opposing effects of HIF1α and HIF2α on chromaffin cell phenotypic features and tumor cell proliferation: Insights from MYCâ€associated factor X. International Journal of Cancer, 2014, 135, 2054-2064.	2.3	72
256	Correlation Between In Vivo ¹⁸ F-FDG PET and Immunohistochemical Markers of Glucose Uptake and Metabolism in Pheochromocytoma and Paraganglioma. Journal of Nuclear Medicine, 2014, 55, 1253-1259.	2.8	67
257	Renaissance of 18F-FDG Positron Emission Tomography in the Imaging of Pheochromocytoma/Paraganglioma. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 2337-2339.	1.8	18
258	The size of the primary tumor and age at initial diagnosis are independent predictors of the metastatic behavior and survival of patients with SDHB-related pheochromocytoma and paraganglioma: a retrospective cohort study. BMC Cancer, 2014, 14, 523.	1.1	55
259	Pheochromocytoma and Paraganglioma: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 1915-1942.	1.8	2,031
260	Association between acute sympathetic response, early onset vasospasm, and delayed vasospasm following spontaneous subarachnoid hemorrhage. Journal of Clinical Neuroscience, 2014, 21, 256-262.	0.8	17
261	The Presence of SDHB Mutations Should Modify Surgical Indications for Carotid Body Paragangliomas. Annals of Surgery, 2014, 260, 158-162.	2.1	50
262	Pheochromocytoma Hypertensive Crisis. , 2014, , 139-147.		1
263	Anti-Cancer Potential of MAPK Pathway Inhibition in Paragangliomas–Effect of Different Statins on Mouse Pheochromocytoma Cells. PLoS ONE, 2014, 9, e97712.	1.1	24
264	A novel EPAS1/HIF2A germline mutation in a congenital polycythemia with paraganglioma. Journal of Molecular Medicine, 2013, 91, 507-512.	1.7	155
265	Double stable isotope ultra performance liquid chromatographic-tandem mass spectrometric quantification of tissue content and activity of phenylethanolamine N-methyltransferase, the crucial enzyme responsible for synthesis of epinephrine. Analytical and Bioanalytical Chemistry, 2013, 405, 1713-1719.	1.9	4
266	Landscape of the mitochondrial Hsp90 metabolome in tumours. Nature Communications, 2013, 4, 2139.	5.8	135
267	Multitracer PET imaging of bone metastases from paraganglioma: peripheral halo of uptake on 18F-FLT PET mismatching with central uptake of 18F-FDOPA, 18F-fluorodopamine, and 18F-FDG. European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40, 1928-1929.	3.3	1
268	Association between sympathetic response, neurogenic cardiomyopathy, and venous thromboembolization in patients with primary subarachnoid hemorrhage. Acta Neurochirurgica, 2013, 155, 1501-1510.	0.9	7
269	Response after Surgical Resection of Metastatic Pheochromocytoma and Paraganglioma: Can Postoperative Biochemical Remission Be Predicted?. Journal of the American College of Surgeons, 2013, 217, 489-496.	0.2	44
270	Plasmaâ€free <i>vs</i> deconjugated metanephrines for diagnosis of phaeochromocytoma. Clinical Endocrinology, 2013, 79, 476-483.	1.2	15

#	Article	IF	CITATIONS
271	Role of Hypoxia and HIF2α in Development of the Sympathoadrenal Cell Lineage and Chromaffin Cell Tumors with Distinct Catecholamine Phenotypic Features. Advances in Pharmacology, 2013, 68, 285-317.	1.2	34
272	Novel HIF2A mutations disrupt oxygen sensing, leading to polycythemia, paragangliomas, and somatostatinomas. Blood, 2013, 121, 2563-2566.	0.6	87
273	Reference intervals for plasma free metanephrines with an age adjustment for normetanephrine for optimized laboratory testing of phaeochromocytoma. Annals of Clinical Biochemistry, 2013, 50, 62-69.	0.8	98
274	Histone deacetylase inhibitors increase glucocerebrosidase activity in Gaucher disease by modulation of molecular chaperones. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 966-971.	3.3	66
275	Genotype and Tumor Locus Determine Expression Profile of Pseudohypoxic Pheochromocytomas and Paragangliomas. Neoplasia, 2013, 15, 435-IN22.	2.3	33
276	Current and Future Trends in the Anatomical and Functional Imaging of Head and Neck Paragangliomas. Seminars in Nuclear Medicine, 2013, 43, 462-473.	2.5	23
277	Pheochromocytoma: Unmasking the Chameleon. , 2013, , 123-148.		3
278	Combined Inhibition of mTORC1 and mTORC2 Signaling Pathways Is a Promising Therapeutic Option in Inhibiting Pheochromocytoma Tumor Growth: In Vitro and In Vivo Studies in Female Athymic Nude Mice. Endocrinology, 2013, 154, 646-655.	1.4	41
279	First Report of Bilateral Pheochromocytoma in the Clinical Spectrum of <i>HIF2A</i> -Related Polycythemia-Paraganglioma Syndrome. Journal of Clinical Endocrinology and Metabolism, 2013, 98, E908-E913.	1.8	54
280	Genetics of pheochromocytoma and paraganglioma syndromes. Current Opinion in Endocrinology, Diabetes and Obesity, 2013, 20, 186-191.	1.2	51
281	Genotype-Specific Abnormalities in Mitochondrial Function Associate with Distinct Profiles of Energy Metabolism and Catecholamine Content in Pheochromocytoma and Paraganglioma. Clinical Cancer Research, 2013, 19, 3787-3795.	3.2	53
282	Succinate Dehydrogenase Mutation Underlies Global Epigenomic Divergence in Gastrointestinal Stromal Tumor. Cancer Discovery, 2013, 3, 648-657.	7.7	288
283	Commentary. Clinical Chemistry, 2013, 59, 1565-1565.	1.5	0
284	New Syndrome of Paraganglioma and Somatostatinoma Associated With Polycythemia. Journal of Clinical Oncology, 2013, 31, 1690-1698.	0.8	129
285	Hypoxia-Inducible Factor Signaling in Pheochromocytoma: Turning the Rudder in the Right Direction. Journal of the National Cancer Institute, 2013, 105, 1270-1283.	3.0	146
286	Functional characterization of nonmetastatic paraganglioma and pheochromocytoma by ¹⁸ Fâ€ <scp>FDOPA PET</scp> : focus on missed lesions. Clinical Endocrinology, 2013, 79, 170-177.	1.2	49
287	Phospho-mTOR is not upregulated in metastaticSDHBparagangliomas. European Journal of Clinical Investigation, 2013, 43, 970-977.	1.7	10
288	Targeting Heat Shock Protein 90 for the Treatment of Malignant Pheochromocytoma. PLoS ONE, 2013, 8, e56083.	1.1	23

#	Article	IF	CITATIONS
289	A New Specific Succinate-Glutamate Metabolomic Hallmark in Sdhx-Related Paragangliomas. PLoS ONE, 2013, 8, e80539.	1.1	39
290	False-negative 123I-MIBG SPECT is most commonly found in SDHB-related pheochromocytoma or paraganglioma with high frequency to develop metastatic disease. Endocrine-Related Cancer, 2012, 19, 83-93.	1.6	106
291	Combined blockade of signalling pathways shows marked anti-tumour potential in phaeochromocytoma cell lines. Journal of Molecular Endocrinology, 2012, 49, 79-96.	1.1	44
292	Staging and Functional Characterization of Pheochromocytoma and Paraganglioma by 18F-Fluorodeoxyglucose (18F-FDG) Positron Emission Tomography. Journal of the National Cancer Institute, 2012, 104, 700-708.	3.0	240
293	Somatic <i>HIF2A</i> Gain-of-Function Mutations in Paraganglioma with Polycythemia. New England Journal of Medicine, 2012, 367, 922-930.	13.9	338
294	<i>MAX</i> Mutations Cause Hereditary and Sporadic Pheochromocytoma and Paraganglioma. Clinical Cancer Research, 2012, 18, 2828-2837.	3.2	277
295	Cerebrospinal Fluid Catecholamine Levels as Predictors of Outcome in Subarachnoid Hemorrhage. Cerebrovascular Diseases, 2012, 33, 173-181.	0.8	32
296	Succinate Dehydrogenase (SDH) D Subunit (SDHD) Inactivation in a Growth-Hormone-Producing Pituitary Tumor: A New Association for SDH?. Journal of Clinical Endocrinology and Metabolism, 2012, 97, E357-E366.	1.8	134
297	Succinate Dehydrogenase Kidney Cancer: An Aggressive Example of the Warburg Effect in Cancer. Journal of Urology, 2012, 188, 2063-2071.	0.2	211
298	Usefulness of [18F]-DA and [18F]-DOPA for PET imaging in a mouse model of pheochromocytoma. Nuclear Medicine and Biology, 2012, 39, 215-226.	0.3	13
299	Subclinical phaeochromocytoma. Best Practice and Research in Clinical Endocrinology and Metabolism, 2012, 26, 507-515.	2.2	76
300	Characterization of two mouse models of metastatic pheochromocytoma using bioluminescence imaging. Cancer Letters, 2012, 316, 46-52.	3.2	22
301	Plasma methoxytyramine: A novel biomarker of metastatic pheochromocytoma and paraganglioma in relation to established risk factors of tumour size, location and SDHB mutation status. European Journal of Cancer, 2012, 48, 1739-1749.	1.3	304
302	NFâ€ÎºB inhibition significantly upregulates the norepinephrine transporter system, causes apoptosis in pheochromocytoma cell lines and prevents metastasis in an animal model. International Journal of Cancer, 2012, 131, 2445-2455.	2.3	34
303	Missense mutations in the human SDHB gene increase protein degradation without altering intrinsic enzymatic function. FASEB Journal, 2012, 26, 4506-4516.	0.2	46
304	New Roles of Carboxypeptidase E in Endocrine and Neural Function and Cancer. Endocrine Reviews, 2012, 33, 216-253.	8.9	95
305	EANM 2012 guidelines for radionuclide imaging of phaeochromocytoma and paraganglioma. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 1977-1995.	3.3	223
306	Warburg Effect's Manifestation in Aggressive Pheochromocytomas and Paragangliomas: Insights from a Mouse Cell Model Applied to Human Tumor Tissue. PLoS ONE, 2012, 7, e40949.	1.1	32

#	Article	IF	CITATIONS
307	Murine Models and Cell Lines for the Investigation of Pheochromocytoma: Applications for Future Therapies?. Endocrine Pathology, 2012, 23, 43-54.	5.2	30
308	Determinants of Central Sympathetic Activation in Spontaneous Primary Subarachnoid Hemorrhage. Neurocritical Care, 2012, 16, 381-388.	1.2	26
309	Measurements of Plasma Methoxytyramine, Normetanephrine, and Metanephrine as Discriminators of Different Hereditary Forms of Pheochromocytoma. Clinical Chemistry, 2011, 57, 411-420.	1.5	282
310	Hypertension in Pheochromocytoma: Characteristics andÂTreatment. Endocrinology and Metabolism Clinics of North America, 2011, 40, 295-311.	1.2	153
311	Current Role of Metaiodobenzylguanidine in the Diagnosis of Pheochromocytoma and Medullary Thyroid Cancer. Seminars in Nuclear Medicine, 2011, 41, 364-368.	2.5	61
312	When is a phaeo not a phaeo? Depression in an adolescent leading to a phaeochromocytomaâ€like biochemical profile. Clinical Endocrinology, 2011, 75, 567-568.	1.2	1
313	Metastatic pheochromocytoma: Does the size and age matter?. European Journal of Clinical Investigation, 2011, 41, 1121-1128.	1.7	42
314	Comparison of clinical and imaging features in succinate dehydrogenase-positive versus sporadic paragangliomas. Surgery, 2011, 150, 1186-1193.	1.0	15
315	CSF Catecholamine Profile in Subarachnoid Hemorrhage Patients with Neurogenic Cardiomyopathy. Neurocritical Care, 2011, 14, 401-406.	1.2	11
316	Functional Imaging of <i>SDHx</i> -Related Head and Neck Paragangliomas: Comparison of ¹⁸ F-Fluorodihydroxyphenylalanine, ¹⁸ F-Fluorodopamine, ¹⁸ F-Fluoro-2-I PET, ¹²³ I-Metaiodobenzylguanidine Scintigraphy, and ¹¹¹ In-Pentetreotide Scintigraphy. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 2779-2785.	Deoxy- <scp 1.8</scp 	o>d-Glu ניין
317	Age at Diagnosis of Pheochromocytoma Differs According to Catecholamine Phenotype and Tumor Location. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 375-384.	1.8	90
318	Drugs and Pheochromocytoma — Don't Be Fooled by Every Elevated Metanephrine. New England Journal of Medicine, 2011, 364, 2268-2270.	13.9	95
319	Increased uptake of [123I]meta-iodobenzylguanidine, [18F]fluorodopamine, and [3H]norepinephrine in mouse pheochromocytoma cells and tumors after treatment with the histone deacetylase inhibitors. Endocrine-Related Cancer, 2011, 18, 143-157.	1.6	37
320	Metastatic Pheochromocytoma/Paraganglioma Related to Primary Tumor Development in Childhood or Adolescence: Significant Link to <i>SDHB</i> Mutations. Journal of Clinical Oncology, 2011, 29, 4137-4142.	0.8	170
321	Bilateral Adrenal Medullary Hyperplasia Associated With an <i>SDHB</i> Mutation. Journal of Clinical Oncology, 2011, 29, e200-e202.	0.8	33
322	Pheochromocytoma and Paraganglioma: Current Functional and Future Molecular Imaging. Frontiers in Oncology, 2011, 1, 58.	1.3	33
323	Drugs and pheochromocytomadon't be fooled by every elevated metanephrine. New England Journal of Medicine, 2011, 364, 2268-70.	13.9	21
324	An N-terminal truncated carboxypeptidase E splice isoform induces tumor growth and is a biomarker for predicting future metastasis in human cancers. Journal of Clinical Investigation, 2011, 121, 880-892.	3.9	61

#	Article	IF	CITATIONS
325	Pharmacologic Modulation of Serine/Threonine Phosphorylation Highly Sensitizes PHEO in a MPC Cell and Mouse Model to Conventional Chemotherapy. PLoS ONE, 2011, 6, e14678.	1.1	32
326	The North American Neuroendocrine Tumor Society Consensus Guideline for the Diagnosis and Management of Neuroendocrine Tumors. Pancreas, 2010, 39, 775-783.	0.5	493
327	Tyrosine hydroxylase, chromogranin A, and steroidogenic acute regulator as markers for successful separation of human adrenal medulla. Cell and Tissue Research, 2010, 340, 607-612.	1.5	15
328	Exercise-induced nausea and vomiting: another sign and symptom of pheochromocytoma and paraganglioma. Endocrine, 2010, 37, 403-407.	1.1	19
329	Genetic Testing for Pheochromocytoma. Current Hypertension Reports, 2010, 12, 456-464.	1.5	56
330	Metastatic Paraganglioma. Seminars in Oncology, 2010, 37, 627-637.	0.8	91
331	Development and validation of a comprehensive mutation and deletion detection assay for SDHB, SDHC, and SDHD. Clinical Biochemistry, 2010, 43, 700-704.	0.8	5
332	New imaging approaches to phaeochromocytomas and paragangliomas. Clinical Endocrinology, 2010, 72, 137-145.	1.2	112
333	Response to Letter to the Editor by Dullaart <i>etÂal.</i> . Clinical Endocrinology, 2010, 72, 569-570.	1.2	0
334	Catecholamine metabolomic and secretory phenotypes in phaeochromocytoma. Endocrine-Related Cancer, 2010, 18, 97-111.	1.6	169
335	Minimal changes in environmental temperature result in a significant increase in energy expenditure and changes in the hormonal homeostasis in healthy adults. European Journal of Endocrinology, 2010, 163, 863-872.	1.9	80
336	Succinate dehydrogenase gene mutations are strongly associated with paraganglioma of the organ of Zuckerkandl. Endocrine-Related Cancer, 2010, 17, 581-588.	1.6	30
337	Factors influencing arterial stiffness in pheochromocytoma and effect of adrenalectomy. Hypertension Research, 2010, 33, 454-459.	1.5	34
338	The Use of Functional Imaging in a Patient with Head and Neck Paragangliomas. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 481-482.	1.8	20
339	Low Sensitivity of Glucagon Provocative Testing for Diagnosis of Pheochromocytoma. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 238-245.	1.8	27
340	SDH-related pheochromocytoma and paraganglioma. Best Practice and Research in Clinical Endocrinology and Metabolism, 2010, 24, 415-424.	2.2	78
341	Gsα Deficiency in Adipose Tissue Leads to a Lean Phenotype with Divergent Effects on Cold Tolerance and Diet-Induced Thermogenesis. Cell Metabolism, 2010, 11, 320-330.	7.2	38
342	In vivo micro-CT imaging of liver lesions in small animal models. Methods, 2010, 50, 20-25.	1.9	38

#	Article	IF	CITATIONS
343	Functional and Oncologic Outcomes of Partial Adrenalectomy for Pheochromocytoma in Patients With von Hippel-Lindau Syndrome After at Least 5 Years of Followup. Journal of Urology, 2010, 184, 1855-1859.	0.2	66
344	Pheochromocytoma and Paraganglioma. Progress in Brain Research, 2010, 182, 343-373.	0.9	58
345	Partial Adrenalectomy: Underused First Line Therapy for Small Adrenal Tumors. Journal of Urology, 2010, 184, 18-25.	0.2	85
346	Monoamine Oxidase A–Mediated Enhanced Catabolism of Norepinephrine Contributes to Adverse Remodeling and Pump Failure in Hearts With Pressure Overload. Circulation Research, 2010, 106, 193-202.	2.0	187
347	Diagnosis of pheochromocytoma with special emphasis on MEN2 syndrome. Hormones, 2009, 8, 111-116.	0.9	36
348	Overexpression of Interleukin-13 Receptor-α2 in Neuroendocrine Malignant Pheochromocytoma: A Novel Target for Receptor Directed Anti-Cancer Therapy. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 2952-2957.	1.8	25
349	Comparison of 18F-Fluoro-L-DOPA, 18F-Fluoro-Deoxyglucose, and 18F-Fluorodopamine PET and 123I-MIBG Scintigraphy in the Localization of Pheochromocytoma and Paraganglioma. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 4757-4767.	1.8	361
350	Mediastinal paragangliomas: association with mutations in the succinate dehydrogenase genes and aggressive behavior. Endocrine-Related Cancer, 2009, 16, 291-299.	1.6	42
351	Clinical aspects of SDHx-related pheochromocytoma and paraganglioma. Endocrine-Related Cancer, 2009, 16, 391-400.	1.6	117
352	Usefulness of ¹²³ I-MIBG Scintigraphy in the Evaluation of Patients with Known or Suspected Primary or Metastatic Pheochromocytoma or Paraganglioma: Results from a Prospective Multicenter Trial. Journal of Nuclear Medicine, 2009, 50, 1448-1454.	2.8	139
353	Noninvasive monitoring of a murine model of metastatic pheochromocytoma: A comparison of contrastâ€enhanced microCT and nonenhanced MRI. Journal of Magnetic Resonance Imaging, 2009, 29, 685-691.	1.9	34
354	Update on pediatric pheochromocytoma. Pediatric Nephrology, 2009, 24, 943-950.	0.9	102
355	Malignant paraganglioma associated with succinate dehydrogenase subunit B in an 8-year-old child: the age of first screening?. Pediatric Nephrology, 2009, 24, 1239-1242.	0.9	17
356	Characterization of an animal model of aggressive metastatic pheochromocytoma linked to a specific gene signature. Clinical and Experimental Metastasis, 2009, 26, 239-250.	1.7	62
357	Use of 6â€[¹⁸ F]â€fluorodopamine positron emission tomography (PET) as firstâ€line investigation for the diagnosis and localization of nonâ€metastatic and metastatic phaeochromocytoma (PHEO). Clinical Endocrinology, 2009, 71, 11-17.	1.2	74
358	Central Nervous System Imprinting of the G Protein Gsα and Its Role in Metabolic Regulation. Cell Metabolism, 2009, 9, 548-555.	7.2	118
359	A Reduction in Pten Tumor Suppressor Activity Promotes ErbB-2-Induced Mouse Prostate Adenocarcinoma Formation through the Activation of Signaling Cascades Downstream of PDK1. American Journal of Pathology, 2009, 174, 2051-2060.	1.9	18
360	An immunohistochemical procedure to detect patients with paraganglioma and phaeochromocytoma with germline SDHB, SDHC, or SDHD gene mutations: a retrospective and prospective analysis. Lancet Oncology, The, 2009, 10, 764-771.	5.1	477

#	Article	IF	CITATIONS
361	Radiofrequency Ablation of Metastatic Pheochromocytoma. Journal of Vascular and Interventional Radiology, 2009, 20, 1483-1490.	0.2	51
362	Candidate Genes Associated With Malignant Pheochromocytomas by Genome-Wide Expression Profiling. Annals of Surgery, 2009, 250, 983-990.	2.1	23
363	Brief Communication: Radiographic Contrast Infusion and Catecholamine Release in Patients With Pheochromocytoma. Annals of Internal Medicine, 2009, 150, 27.	2.0	48
364	Gender-related differences in the clinical presentation of malignant and benign pheochromocytoma. Endocrine, 2008, 34, 96-100.	1.1	16
365	Metastasis-associated gene expression profile of liver and subcutaneous lesions derived from mouse pheochromocytoma cells. Molecular Carcinogenesis, 2008, 47, 245-251.	1.3	15
366	Treatment of malignant pheochromocytoma/paraganglioma with cyclophosphamide, vincristine, and dacarbazine. Cancer, 2008, 113, 2020-2028.	2.0	234
367	Unexplained Symptomatic Paroxysmal Hypertension in Pseudopheochromocytoma. Annals of the New York Academy of Sciences, 2008, 1148, 469-478.	1.8	15
368	Pheochromocytoma. Annals of the New York Academy of Sciences, 2008, 1148, 462-468.	1.8	22
369	Clinical and molecular genetics of patients with the Carney–Stratakis syndrome and germline mutations of the genes coding for the succinate dehydrogenase subunits SDHB, SDHC, and SDHD. European Journal of Human Genetics, 2008, 16, 79-88.	1.4	446
370	Mutations associated with succinate dehydrogenase <scp>d</scp> â€related malignant paragangliomas. Clinical Endocrinology, 2008, 68, 561-566.	1.2	44
371	A clinical overview of pheochromocytomas/paragangliomas and carcinoid tumors. Nuclear Medicine and Biology, 2008, 35, S27-S34.	0.3	64
372	Differential expression of the regulated catecholamine secretory pathway in different hereditary forms of pheochromocytoma. American Journal of Physiology - Endocrinology and Metabolism, 2008, 295, E1223-E1233.	1.8	66
373	Role of positron emission tomography and bone scintigraphy in the evaluation of bone involvement in metastatic pheochromocytoma and paraganglioma: specific implications for succinate dehydrogenase enzyme subunit B gene mutations. Endocrine-Related Cancer, 2008, 15, 311-323.	1.6	60
374	Pheochromocytoma crisis induced by glucocorticoids: a report of four cases and review of the literature. European Journal of Endocrinology, 2008, 158, 423-429.	1.9	86
375	Comparison of 6- ¹⁸ F-Fluorodopamine PET with ¹²³ I-Metaiodobenzylguanidine and ¹¹¹ In-Pentetreotide Scintigraphy in Localization of Nonmetastatic and Metastatic Pheochromocytoma. Journal of Nuclear Medicine, 2008, 49, 1613-1619.	2.8	137
376	Biochemically Silent Abdominal Paragangliomas in Patients with Mutations in the <i>Succinate Dehydrogenase Subunit B</i> Gene. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 4826-4832.	1.8	111
377	Pheochromocytoma. Nature Clinical Practice Cardiovascular Medicine, 2008, 5, E1-E1.	3.3	7
378	Preoperative Management of the Pheochromocytoma Patient. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 4069-4079.	1.8	497

#	Article	IF	CITATIONS
379	Adenoviral Gene Transfer in Bovine Adrenomedullary and Murine Pheochromocytoma Cells: Potential Clinical and Therapeutic Relevance. Endocrinology, 2007, 148, 3900-3907.	1.4	5
380	Elevated Inflammation Markers in Pheochromocytoma Compared to Other Forms of Hypertension. NeuroImmunoModulation, 2007, 14, 57-64.	0.9	38
381	Mitochondrial Localization of Human Recombinant Adenovirus: From Evolution to Gene Therapy. NeuroImmunoModulation, 2007, 14, 221-223.	0.9	5
382	The Incidentally Discovered Adrenal Mass. New England Journal of Medicine, 2007, 356, 2005-2006.	13.9	20
383	Clinical Presentations, Biochemical Phenotypes, and Genotype-Phenotype Correlations in Patients withSuccinate Dehydrogenase Subunit B-Associated Pheochromocytomas and Paragangliomas. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 779-786.	1.8	262
384	Brown Fat Imaging with 18F-6-Fluorodopamine PET/CT, 18F-FDG PET/CT, and 123I-MIBG SPECT: A Study of Patients Being Evaluated for Pheochromocytoma. Journal of Nuclear Medicine, 2007, 48, 1077-1083.	2.8	92
385	The Effects of Carbidopa on Uptake of 6-18F-Fluoro-L-DOPA in PET of Pheochromocytoma and Extraadrenal Abdominal Paraganglioma. Journal of Nuclear Medicine, 2007, 48, 1599-1606.	2.8	101
386	Usefulness of Standardized Uptake Values for Distinguishing Adrenal Glands with Pheochromocytoma from Normal Adrenal Glands by Use of 6-18F-Fluorodopamine PET. Journal of Nuclear Medicine, 2007, 48, 1940-1944.	2.8	23
387	Is Supine Rest Necessary before Blood Sampling for Plasma Metanephrines?. Clinical Chemistry, 2007, 53, 352-354.	1.5	110
388	Superiority of Fluorodeoxyglucose Positron Emission Tomography to Other Functional Imaging Techniques in the Evaluation of Metastatic SDHB-Associated Pheochromocytoma and Paraganglioma. Journal of Clinical Oncology, 2007, 25, 2262-2269.	0.8	316
389	Proteomic profiling of von Hippel–Lindau syndrome and multiple endocrine neoplasia type 2 pheochromocytomas reveals different expression of chromogranin B. Endocrine-Related Cancer, 2007, 14, 463-471.	1.6	14
390	The role of 6-[18F]fluorodopamine positron emission tomography in the localization of adrenal pheochromocytoma associated with von Hippel–Lindau syndrome. European Journal of Endocrinology, 2007, 156, 483-487.	1.9	78
391	Neuropeptide Y expression in phaeochromocytomas: relative absence in tumours from patients with von Hippel–Lindau syndrome. Journal of Endocrinology, 2007, 193, 225-233.	1.2	14
392	Familial pheochromocytomas and paragangliomas associated with mutations of the succinate dehydrogenase genes. Expert Review of Endocrinology and Metabolism, 2007, 2, 399-406.	1.2	2
393	Sympathoadrenal function in patients with paroxysmal hypertension: pseudopheochromocytoma. Journal of Hypertension, 2007, 25, 2286-2295.	0.3	42
394	ErbB-2 Induces Bilateral Adrenal Pheochromocytoma Formation in Mice. Cell Cycle, 2007, 6, 1946-1950.	1.3	17
395	The optimal imaging of adrenal tumours: a comparison of different methods. Endocrine-Related Cancer, 2007, 14, 587-599.	1.6	218
396	Current Treatment of Malignant Pheochromocytoma. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 1217-1225.	1.8	180

#	Article	IF	CITATIONS
397	Adverse Drug Reactions in Patients with Phaeochromocytoma. Drug Safety, 2007, 30, 1031-1062.	1.4	122
398	Pheochromocytoma: recommendations for clinical practice from the First International Symposium. Nature Clinical Practice Endocrinology and Metabolism, 2007, 3, 92-102.	2.9	581
399	An assessment of biochemical tests for the diagnosis of pheochromocytoma. Nature Clinical Practice Endocrinology and Metabolism, 2007, 3, 744-745.	2.9	19
400	Cardiac sympathetic denervation preceding motor signs in Parkinson disease. Clinical Autonomic Research, 2007, 17, 118-121.	1.4	88
401	Emergencies Caused by Pheochromocytoma, Neuroblastoma, or Ganglioneuroma. Endocrinology and Metabolism Clinics of North America, 2006, 35, 699-724.	1.2	65
402	Utility of Plasma Free Metanephrines in Diagnosis of Factitious Pheochromocytoma. Endocrine Practice, 2006, 12, 568-571.	1.1	9
403	Uncommon Endocrine Tumors in Children and Adolescents. , 2006, , 775-797.		1
404	Discordant localization of 2-[18F]-fluoro-2-deoxy-D-glucose in 6-[18F]-fluorodopamine- and [123I]-metaiodobenzylguanidine-negative metastatic pheochromocytoma sites. Nuclear Medicine Communications, 2006, 27, 31-36.	0.5	85
405	Characteristics of Blood Pressure in Pheochromocytoma. Annals of the New York Academy of Sciences, 2006, 1073, 86-93.	1.8	14
406	Transcriptional Regulation of Phenylethanolamine N-Methyltransferase in Pheochromocytomas from Patients with von Hippel-Lindau Syndrome and Multiple Endocrine Neoplasia Type 2. Annals of the New York Academy of Sciences, 2006, 1073, 241-252.	1.8	24
407	Animal Models of Pheochromocytoma Including NIH Initial Experience. Annals of the New York Academy of Sciences, 2006, 1073, 300-305.	1.8	9
408	Biochemical Diagnosis and Localization of Pheochromocytoma: Can We Reach a Consensus?. Annals of the New York Academy of Sciences, 2006, 1073, 332-347.	1.8	115
409	Current Trends in Functional Imaging of Pheochromocytomas and Paragangliomas. Annals of the New York Academy of Sciences, 2006, 1073, 374-382.	1.8	50
410	Anatomical and Functional Imaging of Tumors in Animal Models: Focus on Pheochromocytoma. Annals of the New York Academy of Sciences, 2006, 1073, 392-404.	1.8	11
411	Gene Expression Profiling of Benign and Malignant Pheochromocytoma. Annals of the New York Academy of Sciences, 2006, 1073, 541-556.	1.8	59
412	Somatic VHLgene alterations in MEN2-associated medullary thyroid carcinoma. BMC Cancer, 2006, 6, 131.	1.1	29
413	MicroCT for high-resolution imaging of ectopic pheochromocytoma tumors in the liver of nude mice. International Journal of Cancer, 2006, 119, 2236-2241.	2.3	30
414	High Frequency ofSDHBGermline Mutations in Patients with Malignant Catecholamine-Producing Paragangliomas: Implications for Genetic Testing. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 4505-4509.	1.8	299

KAREL PACAK

#	Article	IF	CITATIONS
415	Increased blood pressure variability in pheochromocytoma compared to essential hypertension patients. Journal of Hypertension, 2005, 23, 2033-2039.	0.3	45
416	Plasma metanephrines in renal failure. Kidney International, 2005, 67, 668-677.	2.6	73
417	Downregulation of metastasis suppressor genes in malignant pheochromocytoma. International Journal of Cancer, 2005, 114, 139-143.	2.3	92
418	Expression of the noradrenaline transporter and phenylethanolamine N-methyltransferase in normal human adrenal gland and phaeochromocytoma. Cell and Tissue Research, 2005, 322, 443-453.	1.5	22
419	Pheochromocytoma Catecholamine Phenotypes and Prediction of Tumor Size and Location by Use of Plasma Free Metanephrines. Clinical Chemistry, 2005, 51, 735-744.	1.5	177
420	Differential Expression of Erythropoietin and Its Receptor in von Hippel-Lindau-Associated and Multiple Endocrine Neoplasia Type 2-Associated Pheochromocytomas. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 3747-3751.	1.8	26
421	Cushing's Syndrome Due to Ectopic Corticotropin Secretion: Twenty Years' Experience at the National Institutes of Health. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 4955-4962.	1.8	588
422	Biochemical and Clinical Manifestations of Dopamine-Producing Paragangliomas: Utility of Plasma Methoxytyramine. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 2068-2075.	1.8	213
423	Different expression of catecholamine transporters in phaeochromocytomas from patients with von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2. European Journal of Endocrinology, 2005, 153, 551-563.	1.9	57
424	Phaeochromocytoma. Lancet, The, 2005, 366, 665-675.	6.3	1,462
425	Combined corticotropin-releasing hormone and glucocorticoid deficiency does not enhance counterregulatory responses after recurrent hypoglycemia in mice. Metabolism: Clinical and Experimental, 2005, 54, 1259-1265.	1.5	7
426	New functional imaging modalities for chromaffin tumors, neuroblastomas and ganglioneuromas. Trends in Endocrinology and Metabolism, 2005, 16, 66-72.	3.1	65
427	Leptin concentrations in the abdominal subcutaneous adipose tissue of patients with anorexia nervosa assessed by in vivo microdialysis. Regulatory Peptides, 2005, 128, 63-68.	1.9	26
428	A New Concept of Unopposed β-Adrenergic Overstimulation in a Patient with Pheochromocytoma. Annals of Internal Medicine, 2005, 142, 1026.	2.0	11
429	Current Approaches and Recommended Algorithm for the Diagnostic Localization of Pheochromocytoma. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 479-491.	1.8	296
430	The Role of [18F]Fluorodeoxyglucose Positron Emission Tomography and [1111n]-Diethylenetriaminepentaacetate-d-Phe-Pentetreotide Scintigraphy in the Localization of Ectopic Adrenocorticotropin-Secreting Tumors Causing Cushing's Syndrome. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 2214-2221.	1.8	133
431	Malignant pheochromocytoma: current status and initiatives for future progress. Endocrine-Related Cancer, 2004, 11, 423-436.	1.6	299
432	Cardiac Uptake-1 Inhibition by High Circulating Norepinephrine Levels in Patients with Pheochromocytoma. Hypertension, 2004, 43, 1227-1232.	1.3	15

#	Article	lF	CITATIONS
433	Diagnosis and Localization of Pheochromocytoma. Hypertension, 2004, 43, 907-910.	1.3	40
434	Functional Imaging of Endocrine Tumors: Role of Positron Emission Tomography. Endocrine Reviews, 2004, 25, 568-580.	8.9	145
435	Anatomical and Functional Imaging of Metastatic Pheochromocytoma. Annals of the New York Academy of Sciences, 2004, 1018, 495-504.	1.8	40
436	Laparoscopic Management of Extra-Adrenal Pheochromocytoma. Journal of Urology, 2004, 171, 72-76.	0.2	50
437	Pheochromocytoma as an endocrine emergency. Reviews in Endocrine and Metabolic Disorders, 2003, 4, 121-128.	2.6	87
438	Diagnostic Localization of Malignant Bladder Pheochromocytoma Using 6-[18 F]Fluorodopamine Positron Emission Tomography. Journal of Urology, 2003, 169, 274-275.	0.2	24
439	Endocrine Withdrawal Syndromes. Endocrine Reviews, 2003, 24, 523-538.	8.9	144
440	Biochemical Diagnosis of Pheochromocytoma: How to Distinguish True- from False-Positive Test Results. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 2656-2666.	1.8	447
441	Superiority of 6-[18F]-Fluorodopamine Positron Emission TomographyVersus[131I]-Metaiodobenzylguanidine Scintigraphy in the Localization of Metastatic Pheochromocytoma. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 4083-4087.	1.8	237
442	Localization of Medullary Thyroid Carcinoma Metastasis in a Multiple Endocrine Neoplasia Type 2A Patient by 6-[18F]-Fluorodopamine Positron Emission Tomography. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 637-641.	1.8	64
443	Loss of Meal-Induced Decrease in Plasma Ghrelin Levels in Patients with Anorexia Nervosa. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 1678-1682.	1.8	142
444	Effects of Hypo- and Hyperthyroidism on Noradrenergic Activity and Glycerol Concentrations in Human Subcutaneous Abdominal Adipose Tissue Assessed with Microdialysis. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 5605-5608.	1.8	48
445	Diagnostic Imaging of Pheochromocytoma. , 2003, 31, 107-120.		12
446	Biochemical Diagnosis of Pheochromocytoma. , 2003, 31, 76-106.		54
447	Hypotension in a Woman with a Metastatic Dopamine-Secreting Carotid Body Tumor. Endocrine Practice, 2003, 9, 310-314.	1.1	25
448	Survivin: a novel neuroendocrine marker for pheochromocytoma. European Journal of Endocrinology, 2002, 146, 381-388.	1.9	31
449	Utility of Plasma Free Metanephrines for Detecting Childhood Pheochromocytoma. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 1955-1960.	1.8	104
450	The Molecular Pathogenesis of Hereditary and Sporadic Adrenocortical and Adrenomedullary Tumors. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 5367-5384.	1.8	174

KAREL PACAK

#	Article	IF	CITATIONS
451	Biochemical Diagnosis of Pheochromocytoma. JAMA - Journal of the American Medical Association, 2002, 287, 1427-34.	3.8	994
452	Management of Malignant Pheochromocytoma. , 2002, 12, 291-299.		11
453	Chronic Hypercortisolemia Inhibits Dopamine Synthesis and Turnover in the Nucleus accumbens: An in vivo Microdialysis Study. Neuroendocrinology, 2002, 76, 148-157.	1.2	41
454	Diagnostic Localization of Pheochromocytoma. Annals of the New York Academy of Sciences, 2002, 970, 170-176.	1.8	60
455	Choice of biochemical test for diagnosis of pheochromocytoma: Validation of plasma metanephrines. Current Hypertension Reports, 2002, 4, 250-255.	1.5	25
456	Local sympathetic function in human skeletal muscle and adipose tissue assessed by microdialysis. Clinical Autonomic Research, 2002, 12, 13-19.	1.4	10
457	Somatic VHL gene deletion and point mutation in MEN 2A-associated pheochromocytoma. Oncogene, 2002, 21, 479-482.	2.6	33
458	New Insights into the Genetics of Familial Chromaffin Cell Tumors. Annals of the New York Academy of Sciences, 2002, 970, 11-28.	1.8	54
459	New Advances in the Biochemical Diagnosis of Pheochromocytoma. Annals of the New York Academy of Sciences, 2002, 970, 29-40.	1.8	68
460	Genomic Medicine. Annals of the New York Academy of Sciences, 2002, 970, 177-192.	1.8	3
461	Pheochromocytoma in von Hippel-Lindau Disease: Distinct Histopathologic Phenotype Compared to Pheochromocytoma in Multiple Endocrine Neoplasia Type 2. Endocrine Pathology, 2002, 13, 17-28.	5.2	74
462	The role of dopamine in methylene blue-mediated inhibition of estradiol benzoate-induced anterior pituitary hyperplasia in rats. Neuroscience Letters, 2001, 304, 194-198.	1.0	4
463	INCREASED PLASMA NOREPINEPHRINE CONCENTRATION IN CATS WITH INTERSTITIAL CYSTITIS. Journal of Urology, 2001, 165, 2051-2054.	0.2	64
464	Recent Advances in Genetics, Diagnosis, Localization, and Treatment of Pheochromocytoma. Annals of Internal Medicine, 2001, 134, 315.	2.0	512
465	Understanding catecholamine metabolism as a guide to the biochemical diagnosis of pheochromocytoma. Reviews in Endocrine and Metabolic Disorders, 2001, 2, 297-311.	2.6	156
466	Allelic imbalance of the mutant and wild-type RET allele in MEN 2A-associated medullary thyroid carcinoma. Oncogene, 2001, 20, 7809-7811.	2.6	46
467	Pheochromocytomas in von Hippel-Lindau Syndrome and Multiple Endocrine Neoplasia Type 2 Display Distinct Biochemical and Clinical Phenotypes. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 1999-2008.	1.8	262
468	6-[¹⁸ F]Fluorodopamine Positron Emission Tomographic (PET) Scanning for Diagnostic Localization of Pheochromocytoma. Hypertension, 2001, 38, 6-8.	1.3	215

#	Article	IF	CITATIONS
469	Radiofrequency Ablation: a Novel Approach for Treatment of Metastatic Pheochromocytoma. Journal of the National Cancer Institute, 2001, 93, 648-649.	3.0	83
470	A "Pheo―Lurks: Novel Approaches for Locating Occult Pheochromocytoma. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 3641-3646.	1.8	51
471	INCREASED PLASMA NOREPINEPHRINE CONCENTRATION IN CATS WITH INTERSTITIAL CYSTITIS. Journal of Urology, 2001, 165, 2051-2054.	0.2	25
472	CRH Deficiency Impairs but Does Not Block Pituitary-Adrenal Responses to Diverse Stressors. Neuroendocrinology, 2000, 71, 79-87.	1.2	68
473	Impaired Basal and Restraint-Induced Epinephrine Secretion in Corticotropin-Releasing Hormone- Deficient Mice ¹ . Endocrinology, 2000, 141, 1142-1150.	1.4	78
474	Paternal versus maternal transmission of a stimulatory G-protein \hat{I}_{\pm} subunit knockout produces opposite effects on energy metabolism. Journal of Clinical Investigation, 2000, 105, 615-623.	3.9	151
475	How do levels of (endogenous) glucocorticoids, interleukin-10 and interleukin-12 relate to multiple sclerosis relapse before, during and after pregnancy?. Clinical Endocrinology, 1999, 50, 818-819.	1.2	7
476	Heterogeneous neurochemical responses to different stressors: a test of Selye's doctrine of nonspecificity. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 1998, 275, R1247-R1255.	0.9	119
477	Regulation of Peripheral Catecholamine Responses to Acute Stress in Young Adult and Aged F-344 Rats. Stress, 1997, 2, 113-122.	0.8	15
478	Stressor-Specific Activation of Catecholaminergic Systems: Implications for Stress-Related Hypothalamic-Pituitary-Adrenocortical Responses. Advances in Pharmacology, 1997, 42, 561-564.	1.2	27
479	Hyperinsulinemia and Sympathoadrenal System Activity in the Rat. Annals of the New York Academy of Sciences, 1997, 827, 118-134.	1.8	11
480	Chronic blockade of nitric oxide synthesis elevates plasma levels of catecholamines and their metabolites at rest and during stress in rats. Neurochemical Research, 1997, 22, 995-1001.	1.6	23
481	Triiodothyronine attenuates estradiol-induced increases in dopamine D-2 receptor number in rat anterior pituitary. Brain Research, 1996, 712, 148-152.	1.1	11
482	Interrelations between Sympathoadrenal System andHypothalamo-Pituitary-Adrenocortical/Thyroid Systemsin Rats Exposed to Cold Stress. Journal of Neuroendocrinology, 1996, 8, 533-541.	1.2	64
483	Brainstem Hemisection Decreases Corticotropin-Releasing Hormone mRNA in the Paraventricular Nucleus but not in the Central Amygdaloid Nucleus. Journal of Neuroendocrinology, 1996, 8, 543-551.	1.2	31
484	Disprocynium24, a novel inhibitor of the extraneuronal monoamine transporter, has potent effects on the inactivation of circulating noradrenaline and adrenaline in conscious rat. Naunyn-Schmiedeberg's Archives of Pharmacology, 1996, 354, 287-94.	1.4	34
485	Plasma Metadrenalines: Do they Provide Useful Information about Sympatho-Adrenal Function and Catecholamine Metabolism?. Clinical Science, 1995, 88, 533-542.	1.8	105
486	Stress-Induced Norepinephrine Release in the Hypothalamic Paraventricular Nucleus and Pituitary-Adrenocortical and Sympathoadrenal Activity: In Vivo Microdialysis Studies. Frontiers in Neuroendocrinology, 1995, 16, 89-150.	2.5	348

#	Article	IF	CITATIONS
487	Effects of immobilization on in vivo release of norepinephrine in the bed nucleus of the stria terminalis in conscious rats. Brain Research, 1995, 688, 242-246.	1.1	92
488	Effects of hypercortisolemia or hyperinsulinemia on neurochemical indices of catecholamine release and synthesis in conscious rats. Journal of the Autonomic Nervous System, 1995, 54, 104-112.	1.9	2
489	Effects of Various Stressors on In Vivo Norepinephrine Release in the Hypothalamic Paraventricular Nucleus and on the Pituitary-Adrenocortical Axis. Annals of the New York Academy of Sciences, 1995, 771, 115-130.	1.8	141
490	The neuronal and extraneuronal origins of plasma 3-methoxy-4-hydroxyphenylglycol in rats. Journal of the Autonomic Nervous System, 1994, 50, 93-107.	1.9	39
491	Role of CRH in Glucopenia-Induced Adrenomedullary Activation in Rats. Journal of Neuroendocrinology, 1993, 5, 475-486.	1.2	30
492	Glycine stimulates striatal dopamine release in conscious rats. British Journal of Pharmacology, 1993, 110, 50-53.	2.7	37
493	Effects of Single or Repeated Immobilization on Release of Norepinephrine and Its Metabolites in the Central Nucleus of the Amygdala in Conscious Rats. Neuroendocrinology, 1993, 57, 626-633.	1.2	64
494	Stress-Induced Norepinephrine Release in the Paraventricular Nucleus of Rats with Brainstem Hemisections: A Microdialysis Study. Neuroendocrinology, 1993, 58, 196-201.	1.2	62
495	Noradrenergic activation in the paraventricular nucleus during acute and chronic immobilization stress in rats: an in vivo microdialysis study. Brain Research, 1992, 589, 91-96.	1.1	110
496	Sympathoneural and skeletal muscle contributions to plasma DOPA responses in pithed rats. Journal of the Autonomic Nervous System, 1991, 35, 169-174.	1.9	3
497	Pediatric Metastatic Pheochromocytoma and Paraganglioma: Clinical Presentation and Diagnosis, Genetics, and Therapeutic Approaches. Frontiers in Endocrinology, 0, 13, .	1.5	6